About 25% of the effects of GLP-1 drugs on the kidney are likely attributable to blood pressure and glucose improvements, Orandi told Healio
Heads-up Trying to do it right when it comes to nutrition may feel tempting, but it can backfire
Pro tip: Get personalized recommendations on supplements that support hard-working organs like your liver with a quick quiz
Overall, these findings highlight the promising yet preliminary nature of BPC-157 and TB-500 research and reinforce the urgent need for standardized, large-scale clinical trials and robust safety monitoring frameworks before these compounds can be confidently integrated into clinical practice
You may have seen microdosing of GLP-1s advertised with promises of fewer side effects and better longevity, though there's no clear scientific definition of microdosing, and we dont yet have data to know if these medications prolong life (except for people with known cardiovascular disease)
Our 2025 study in JMIR Formative Research examined 12-month outcomes for participants using semaglutide with behavioural support and found 1 : 19.1% average weight loss at 12 months for active subscribers 77.7% achieved at least 10% weight loss 61.5% achieved at least 15% weight loss 69% reported no side effects by month 12 These are completer results (people who stayed on the programme for 12 months), not intent-to-treat
